Venture Investing in Science


Book Description

Over the past decade, software companies have increasingly monopolized the flow of venture capital, starving support for scientific research and its transformative discoveries. New medicines, cheaper and faster personal computers, and other life-changing developments all stem from investment in science. In the past, these funds led to steam engines, light bulbs, microprocessors, 3D printers, and even the Internet. In Venture Investing in Science, the venture capitalist Douglas W. Jamison and the investment author Stephen R. Waite directly link financial support to revolutionary advancements in physics, computers, chemistry, and biology and make a passionate case for continued investing in science to meet the global challenges of our time. Clean air and water, cures for intractable diseases, greener public transportation, cheaper and faster communication technologies—these are some of the rich opportunities awaiting venture capital investment today. Jamison and Waite focus on how early-stage companies specializing in commercializing transformative technologies based on deep science have been shunned by venture capitalists, and how the development of such companies have been hampered by structural changes in capital markets and government regulation over the past decade. The authors argue that reinvigorating science-based technological innovation is crucial to reactivating the economic dynamism that lifts living standards and fuels prosperity over time.




Financing Life Science Innovation


Book Description

Financing Life Science Innovation reviews the literature on venture capital, corporate governance, and life science venturing and presents a study of the Swedish life science industry and the venture capital investors being active in financially and managerially supporting life science start-up firms.




Life Sciences Venture Capital


Book Description

Managing directors and partners from ten of the nation's leading VC firms on spotting the best investments in life sciences.




Venture Capital Due Diligence


Book Description

Due Diligence ist ein Prüfverfahren, mit dessen Hilfe Investoren die wirtschaftliche und finanzielle Situation des zu finanzierenden Unternehmens genau durchleuchten, um solide Investmententscheidungen zu treffen. "Venture Capital Due Diligence" ist ein praktischer Leitfaden zum Due Diligence Prozess. Er erläutert ausführlich das strenge Regelwerk dieses Prüfverfahrens und zeigt dem Leser, wie er diese Technik in der Praxis einsetzt, um damit Investmentchancen zu bewerten und die Rentabilität seiner Kapitalanlage (ROI - Return on Investment) einzuschätzen. Mit Tipps, Ratschlägen und Checklisten, die von den international erfolgreichsten Wagniskapitalgebern zusammengestellt wurden sowie einem Fragenkatalog, der die wichtigsten Kriterien des Due Diligence Prozesses beinhaltet. "Venture Capital Due Diligence" ist ein unentbehrlicher Ratgeber für alle Venture Capitalists, professionelle Investoren und Finanzgeber.




Seed-stage Venture Investing


Book Description

Seed-Stage Venture Investing, 2nd Edition takes a fresh look at the world of start ups, focusing on life-science and technology spin-outs from academic and biomedical research centers. This book provides a substantial update to the previous edition, explaining the current challenges of financing research-intensive academic spin-outs and offering new insights and advice about evaluating technology, navigating the technology transfer process, developing intellectual property, and applying for grant funding under the NIH SBIR Program. Focusing on real-world, practical information for academic faculty members, PhD students, and post-docs, as well as business entrepreneurs, start-up managers, and new investors, Seed-Stage Venture Investing, 2nd Edition cuts to the chase, eliminating dated material from the previous edition and adding new, tell-it-like-it-is material from veteran practitioners. Book jacket.




The Power Law


Book Description

Shortlisted for the Financial Times Business Book of the Year “A gripping fly-on-the-wall story of the rise of this unique and important industry based on extensive interviews with some of the most successful venture capitalists.” - Daniel Rasmussen, Wall Street Journal “A must-read for anyone seeking to understand modern-day Silicon Valley and even our economy writ large.” -Bethany McLean, The Washington Post "A rare and unsettling look inside a subculture of unparalleled influence.” —Jane Mayer "A classic...A book of exceptional reporting, analysis and storytelling.” —Charles Duhigg From the New York Times bestselling author of More Money Than God comes the astonishingly frank and intimate story of Silicon Valley’s dominant venture-capital firms—and how their strategies and fates have shaped the path of innovation and the global economy Innovations rarely come from “experts.” Elon Musk was not an “electric car person” before he started Tesla. When it comes to improbable innovations, a legendary tech VC told Sebastian Mallaby, the future cannot be predicted, it can only be discovered. It is the nature of the venture-capital game that most attempts at discovery fail, but a very few succeed at such a scale that they more than make up for everything else. That extreme ratio of success and failure is the power law that drives the VC business, all of Silicon Valley, the wider tech sector, and, by extension, the world. In The Power Law, Sebastian Mallaby has parlayed unprecedented access to the most celebrated venture capitalists of all time—the key figures at Sequoia, Kleiner Perkins, Accel, Benchmark, and Andreessen Horowitz, as well as Chinese partnerships such as Qiming and Capital Today—into a riveting blend of storytelling and analysis that unfurls the history of tech incubation, in the Valley and ultimately worldwide. We learn the unvarnished truth, often for the first time, about some of the most iconic triumphs and infamous disasters in Valley history, from the comedy of errors at the birth of Apple to the avalanche of venture money that fostered hubris at WeWork and Uber. VCs’ relentless search for grand slams brews an obsession with the ideal of the lone entrepreneur-genius, and companies seen as potential “unicorns” are given intoxicating amounts of power, with sometimes disastrous results. On a more systemic level, the need to make outsized bets on unproven talent reinforces bias, with women and minorities still represented at woefully low levels. This does not just have social justice implications: as Mallaby relates, China’s homegrown VC sector, having learned at the Valley’s feet, is exploding and now has more women VC luminaries than America has ever had. Still, Silicon Valley VC remains the top incubator of business innovation anywhere—it is not where ideas come from so much as where they go to become the products and companies that create the future. By taking us so deeply into the VCs’ game, The Power Law helps us think about our own future through their eyes.




Capitalizing on Investments in Science and Technology


Book Description

Although the United States is currently capitalizing on its investment in science and technology effectively, there remains much room for improvement. This volume identifies the ingredients for success in capitalizing on such investments to produce national benefits, assesses current U.S. performance, and identifies future challenges. The book cites specific examples and examines several cross-cutting issues. It explores the possibility that the national research portfolio is losing diversity as a result of less long-term research in critical fields such as networking and materials. It also examines the implications of imbalances in the supply of and demand for science and engineering talent in emerging interdisciplinary fields such as bioinformatics.




Innovation, Commercialization, and Start-Ups in Life Sciences


Book Description

Innovation is a translation of a new method, idea, or product into reality and profit. It is a process of connected steps that accumulates into a brand reputation required for success. Unlike Fortune 500 companies, whose projects are self-funded, a start-up must simultaneously have a value proposition that attracts a customer (for revenue), investors (for capital), and acquirers (for a liquidity event or IPO). A high percentage of start-ups fail before attaining positive cashflow, due to a variety of reasons that are detailed in this book. Avoiding the pitfalls and wrong turns are the goals of this book. Innovation, Commercialization, and Start-Ups in Life Sciences details the methodologies necessary to create a successful life science start-up from initiation to exit. Written by an expert who has worked with more nearly 500 life science start-ups, this book discusses specific processes and investor milestones that must be navigated to align customer, funder, and acquirer needs. Successful commercialization requires attention to multiple constituents, such as investors, regulators, and customers. Investors require liquidity for their return, which is achieved through selling their stock in a public or private sale. The reader will gain an appreciation for the necessary data, partnerships, and skills needed to create a competitive and sustainable company. The author discusses such specific issues as customer problems, demonstrating sales access, and ensuring intellectual property is impervious to competitive advancement. This book is intended to be suitable for entrepreneurs, venture capitalists, and investors in both business and academic settings. These organizations have specific departments, such as R&D, operations, business development, legal, regulatory, and marketing, that would also benefit from this book. FEATURES Focuses specifically on life science start-ups Examines how to determine a company valuation and future "fundable milestones" Explores how to align regulatory and clinical strategies Discusses intellectual property derived from a university or individual through formation to exit. Reviews how start‐ups must simultaneously meet the needs of multiple constituencies at once: investors, regulators, customers and exit candidates James F. Jordan is an author, consultant, and speaker. He is a Distinguished Service Professor of Healthcare & Biotechnology Management, a former Fortune 100 executive, and a managing director of a venture fund. Access the Support Material: https://healthcaredata.center/ Cover design by Sarah Mailhott.




VC


Book Description

From nineteenth-century whaling to a multitude of firms pursuing entrepreneurial finance today, venture finance reflects a deep-seated tradition in the deployment of risk capital in the United States. Tom Nicholas’s history of the venture capital industry offers a roller coaster ride through America’s ongoing pursuit of financial gain.